Prophylaxis of Altitude Sickness

Primary Prevention Strategies

Slow, gradual ascent is the most effective prevention method, with recommended rates of 300-600 m/day above 2500m, as recommended by the American Heart Association 1, 2
Include a rest day for every 600-1200m of elevation gained, as suggested by the American Heart Association 1, 3
Avoid vigorous physical exertion before proper acclimatization, as advised by the American Heart Association 2
Delay further ascent if initial symptoms of altitude sickness appear, as recommended by the American Heart Association 1

Pharmacological Prophylaxis

The American Heart Association recommends acetazolamide as the first-line prophylactic medication for altitude sickness, with a standard dose of 250 mg twice daily or 500 mg once daily 1
Acetazolamide has a mechanism of action as a carbonic anhydrase inhibitor, causing mild diuresis and metabolic acidosis, which stimulates ventilation and improves oxygenation, as described by the Journal of Travel Medicine and the European Heart Journal 4, 5
Nifedipine is particularly effective for prevention of high-altitude pulmonary edema (HAPE), as recommended by the American Heart Association 1, 3
Dexamethasone is an alternative when acetazolamide is contraindicated, as suggested by the American Heart Association 1, 3

Special Considerations

Patients with cardiovascular disease should continue pre-existing medications at high altitude, as recommended by the European Heart Journal 6, 7
Acetazolamide may reduce the risk of subendocardial ischemia at high altitude in healthy subjects, as described by the European Heart Journal 8, 9
For patients with heart failure, acetazolamide should be carefully evaluated when used with other diuretics due to risk of dehydration and electrolyte imbalances, as advised by the European Heart Journal 6, 8
Hypertensive patients may benefit from acetazolamide, which can lower blood pressure at high altitude while improving oxygen saturation, as described by the European Heart Journal 5

Pediatric Patients

No randomized trials exist for prevention or treatment of HAPE in children, as noted by the American Heart Association 1, 3
Recommendations for children are based on adult trials, as suggested by the American Heart Association 1
Same principles apply: slow ascent, proper acclimatization, and similar medication dosing adjusted for weight, as recommended by the American Heart Association 2, 3

Common Pitfalls and Caveats

Underestimating the importance of gradual ascent and proper acclimatization, as warned by the American Heart Association 1
Inadequate hydration can worsen symptoms, as described by the Journal of Travel Medicine 4, 10

Altitude Sickness Medication Guidelines

Prevention and Treatment

For patients with a history of High Altitude Pulmonary Edema (HAPE), nifedipine should be started with ascent and continued for 3-4 days after arrival at terminal altitude 11
Immediate descent to lower altitude and supplemental oxygen are primary therapies for High Altitude Pulmonary Edema (HAPE), with nifedipine as the medication of choice 11
PDE5 inhibitors (sildenafil, tadalafil) may be alternatives to nifedipine for HAPE prevention, but tadalafil has been associated with severe acute mountain sickness in some subjects 11

Prevention of Altitude Sickness

Special Considerations

The American College of Sports Medicine suggests that although there is no clear evidence of greater vulnerability to acute mountain sickness in women, sex-dependent physiological reactions may contribute to increased vulnerability in some women, and solutions such as adequate acclimatization, slow ascent rate, and/or preventive medication (acetazolamida) may be necessary 12
The American College of Sports Medicine recommends that targeted training of the respiratory muscles could be a valuable preparation for altitude exposure in women 13
The American College of Sports Medicine notes that sex hormones influence responses to hypoxia, and phases of the hormonal/menstrual cycle may be factors in acclimatization 12, 13

High-Risk Populations

Individuals with a previous episode of high-altitude pulmonary edema (HAPE) have a recurrence rate of 62% with rapid ascent to 4559 m, and require prophylaxis with nifedipina 14

General Prevention

More than 50% of unacclimatized individuals develop acute mountain sickness above 4500 m with rapid ascent (>300 m/day), highlighting the importance of gradual ascent and adequate acclimatization 14

Altitude Sickness Prevention and Treatment

Patient Management

The European Society of Cardiology recommends that patients with pre-existing cardiovascular conditions continue their regular medications throughout altitude exposure, and acetazolamide can be added for AMS prevention using the same 2-3 day post-arrival duration 15, 16
The European Society of Cardiology notes that acetazolamide may reduce subendocardial ischemia risk at high altitude 16
Prolonged use of acetazolamide beyond 2-3 days at terminal altitude is unnecessary for standard AMS prevention and increases cumulative side effects, according to the European Respiratory Review 17
Common adverse effects of acetazolamide include paresthesias, vertigo, and unpleasant taste, which are generally mild but dose-related, as reported in the European Respiratory Review 17, 18

Evidence‑Based Recommendations for Altitude Illness Prevention and Management

Prophylactic Pharmacologic Strategies

Dexamethasone

Dexamethasone may be combined with other agents in individuals at high risk for acute mountain sickness to enhance prophylaxis. 19

Nifedipine for HAPE Prevention

In persons with a prior episode of high‑altitude pulmonary edema (HAPE), extended‑release nifedipine 20 mg every 8 hours should be initiated with ascent and continued for 3–4 days after reaching the target altitude. 19
Extended‑release nifedipine reduces the incidence of HAPE from 64 % to 10 % in HAPE‑susceptible climbers. 19

PDE5 Inhibitors (Second‑Line)

Sildenafil or tadalafil can be used as second‑line agents for HAPE prophylaxis, but they have been associated with severe acute mountain sickness in some subjects. 19

Pediatric Considerations

No randomized controlled trials have evaluated altitude‑illness prophylaxis in children; recommendations are therefore extrapolated from adult data. 19

Non‑Pharmacologic Prevention (Foundational Measures)

Ascend at a rate of 300–600 m per day once above 2 500 m to minimize risk of altitude illness. 19
Incorporate a rest day for every 600–1 200 m of cumulative elevation gain. 19
Avoid vigorous physical exertion before adequate acclimatization has been achieved. 19
Delay any further ascent if early altitude‑related symptoms (e.g., headache, nausea) appear. 19

Acute Management of Established Illness

Immediate descent to a lower altitude is the primary therapy for both acute mountain sickness and high‑altitude pulmonary edema. 19

Critical Pitfalls to Avoid

Continuing ascent despite the presence of early symptoms markedly increases the risk of severe altitude illness and should be avoided. 19

Evidence‑Based Recommendations for Altitude Illness Prevention and Management

Pre‑Acclimatization Strategies

A two‑week pre‑acclimatization program that includes > 8 hours per day at progressively higher elevations improves tolerance to high altitude and reduces the incidence of acute mountain sickness. 20

Sex‑Specific Considerations

Women have a statistically higher risk of developing acute mountain sickness compared with men and therefore should be monitored more closely during ascent. 20
Systematic screening of women using the Lake Louise Symptom Score is recommended to identify early signs of altitude illness. 20
Iron supplementation of approximately 200 mg daily is advisable for women, who are at greater risk of iron deficiency that can impair acclimatization. 20

Cardiovascular Patient Guidance

In hypertensive individuals, acetazolamide may provide an additional blood‑pressure‑lowering benefit, supporting its use in this population at altitude. 21